Latest news with #Alpenglow
NZ Autocar
4 hours ago
- Automotive
- NZ Autocar
Will Alpine launch a hydrogen-powered supercar eventually?
Alpine is continuing with development of its hydrogen-powered Alpenglow concept, now evolved into the Hy4 prototype. First revealed in 2022, the Alpenglow's transformation into the Hy4 suggests Alpine is increasingly serious about hydrogen combustion technology. The Hy4, built on a Ligier LMP3 racing chassis, swaps the original single-seat layout for a more conventional two-seat set-up, suggesting a shift towards a road orientation. The Hy4 was set to debut at the World Endurance Championship in Spa-Francorchamps, Belgium. However, an electrical fault prevented that. Alpine's design chief, Antony Villain, is still optimistic. He said that the Alpenglow was always envisioned for both road and track ends. Villain added that Alpine is considering a small production run of the hydrogen-powered supercar. He stressed that both hydrogen-combustion and battery-electric technologies are being pursued at present. Development was always aimed at eventual production, he said, calling the Alpenglow more of a 'programme' than a concept. Future versions will evolve with improved styling and added everyday utility. A critical part of this update is a new V6 hydrogen engine being developed entirely in-house by Alpine. It is set to replace the existing turbocharged 2.0-litre four-cylinder sourced from motorsport partner Oreca. The new V6 should add both power and efficiency. The Hy4's range currently stands at around 100km at race pace. Le Mans racers generally run 10–20 laps of the 14km circuit before refueling so added efficiency is an imperative. Racing vehicles director François Champod stressed the engine will offer accessible, user-friendly power, unlike a high-revving F1 unit. There are still engineering challenges to overcome. Alpine's hydrogen engineer, Pierre-Jean Tardy, explained that while hydrogen combustion produces similar engine response and sound to petrol, it behaves differently. Running lean for efficiency and low NOx emissions leads to cooler exhaust gases, creating challenges for turbochargers, especially increased lag. In addition, hydrogen's wide flammability range complicates combustion control, increasing the risk of engine knock. Mixing hydrogen gas with air uniformly is another major stumbling block, especially at high engine speeds. Hydrogen is injected at very high velocities, making it harder to mix properly and increasing the risk of abnormal combustion. Temperature management within each combustion chamber must also be uniform to avoid reliability issues. Alpine acknowledges that its hydrogen-combustion technology is in its infancy. The V6 has only recently begun testing on a dynamometer. But the goal is to power the Alpenglow with hydrogen by year's end. While Alpine is eyeing entry into the hydrogen-combustion class at the 2027 Le Mans 24 Hours, it has not made a formal commitment yet. A road-going hydrogen car from Alpine remains a long-term possibility. Champod warned that the broader hydrogen infrastructure will determine its future. The current hydrogen refueling network can only support a limited number of vehicles. However, Renault Group's Hyvia venture, focused on hydrogen-powered vans, could aid infrastructure development. Trucks and light commercial vehicles (LCVs) are expected to lead the rollout of hydrogen stations, indirectly supporting niche vehicles like the Alpenglow. Fuel storage on board remains a significant challenge. Hydrogen tanks require more space than petrol equivalents—over 350 litres versus 50 litres—posing packaging problems. Moreover, Alpine insists hydrogen use must be 'clean' to justify its environmental benefits. That means only decarbonized hydrogen (with carbon capture) or green (via renewable-powered electrolysis).
Miami Herald
3 days ago
- Automotive
- Miami Herald
Alpine to Launch 1000HP Hybrid Supercar in 2028 with Le Mans-Derived V6
Alpine, a historic French sportscar maker best known in the Americas as a Formula One and World Endurance entrant, is to launch a supercar in 2028. It will have around 1000 horsepower, says CEO Phillippe Krief. Most of that comes from a mid-mounted V6 driving the rear wheels. It's augmented by two torque-vectoring electric motors, one for each front wheel. The V6, Krief says, will be developed by the same engineers who do the Le Mans powertrain. The car will use aluminum and carbon-fiber in its construction. Alpine showed a hypercar concept called the Alpenglow three years ago, and afterward it ran, using a hydrogen-combusting V6 to explore this as a race fuel. It looked wonderful, but Krief dismisses the suggestion that the new supercar will bear a resemblance. He points out that the Alpenglow was built with the dimensions of a Le Mans car. "This will be a road car, very different." Krief was technical director at Ferrari before taking the Alpine job, so we might take him seriously when he mentions the SF90 in context of this Alpine supercar. Alpine is a member of the Renault Group, and recently launched two sporty EVs, a subcompact hot hatchback called the A290, and a fastback compact, the A390. The A390 distinguishes itself with a three-motor layout providing torque vectoring for claimed high agility. Total output is 470 hp. If you struggle to see the connection between two small EV five-doors and a hypercar, note that Alpine is launching cars to bridge the gap. For seven years, it has been building a sublime little ICE mid-engined two-seater called the A110. In 2026, a new A110 will launch. Although fully electric, it will be a true sports car. The battery pack will be split in two, some behind the two seats and some in front, to ensure the seating position is low to the road. It will use an in-wheel motor for each rear tire. Krief says vehicle mass will be about the same as a comparable piston-engine car, the Porsche Boxster. Copyright 2025 The Arena Group, Inc. All Rights Reserved.
Business Mayor
20-05-2025
- Business
- Business Mayor
Solana set for biggest protocol overhaul yet with ‘Alpenglow' upgrade
Solana is entering a whole new era with the launch of Alpenglow. Price always depends on whether the market buys the vision. Solana [SOL] has firmly secured its spot among the top L1s, thanks to its unique Proof-of-History architecture that's delivered on speed, throughput, and cost-efficiency. But things are about to level up. Behind the scenes, Solana's devs are pushing boundaries with protocol-level changes aimed at unlocking serious long-term value. The upcoming 'Alpenglow upgrade', with its shift to Votor and Rotor, is set to reduce network latency. Yet, long-term holder conviction in SOL remains razor-thin. Clearly, the market wants more than innovation; it wants results. The question now is: Can Solana turn this technical progress into sustained price action? Solana sets a new standard for decentralization Sure, Solana's Proof-of-History (PoH) mechanism has already set it apart from other L1 blockchains. But with the Alpenglow upgrade, PoH gets replaced by two new components – Votor and Rotor, which are all about making the network faster and more efficient. They slash finality times from over 12 seconds to about 150 milliseconds. Basically instant, matching the speed of centralized systems. Source: That's a big deal. Older consensus methods just couldn't keep up with centralized tech for real-time apps like gaming or finance. Alpenglow changes that, bringing Solana's speed into the same league. This could be the key to making decentralized networks actually practical for every day, real-world applications. In short, making Solana ' ready' for the next wave of blockchain use cases. Protocol advancements in a shaky market Solana developers are clearly playing the long game, engineering the protocol for long-term scalability and performance. Hence, giving Solana a clear technical edge over other L1s. Read More REN decouples from market – did the sharks play a role? Price-wise, however, SOL is still stuck where it was three months ago – no breakout, no real momentum. And whales seem to be losing patience. One major holder just moved over 186k SOL (worth $31 million) to Coinbase after 10 months of staking. Despite earning over 11k SOL in rewards, they're sitting on a $823k loss. This reveals a growing disconnect—solid fundamentals but sluggish price action. The downturn could be driven by macroeconomic uncertainty or lingering market caution around SOL's valuation. Either way, the technology is advancing faster than sentiment. Meanwhile, retail participation continues to rise, with wallets holding over 0.01 SOL reaching a record 11.16 million. Source: Glasssnode According to AMBCrypto, if the Alpenglow upgrade delivers, some of these small holders could become long-term investors, helping SOL finally get priced right.
Yahoo
06-05-2025
- Business
- Yahoo
New Inverted Light-Sheet Microscopy Platform for Research and Clinical Applications
"We are excited to collaborate with Alpenglow and leverage their deep expertise in AI and software development," said Dr. Michael Albiez, Head of ZEISS Research Microscopy Solutions. "This partnership combines Alpenglow's rapidly growing reputation with pharmaceutical companies and clinicians with the leadership of ZEISS in light-sheet microscopy, enabling the creation of powerful, fully integrated workflows for 3D pathology, from sample to analytics." "Partnering with ZEISS represents a significant step forward in our mission to revolutionize pathology by extracting and analysing the wealth of information contained in every single cell of a biopsy, rather than relying on just a small fraction of the tissue," said Dr. Nicholas Reder, CEO of Alpenglow Biosciences. "ZEISS's long-standing history of innovation in light-sheet microscopy is the perfect complement to our cutting-edge software and AI capabilities. Together, we will innovate and expand our existing 3D pathology platform that not only advances the needs of biopharma but also transforms clinical practice." By combining the industry-leading technologies of Alpenglow and ZEISS, the collaboration will enable the broader adoption of 3D pathology across research, translational and clinical applications. As part of the multi-phased collaboration, the companies will develop key applications in: Enhanced 3D pathology workflows (enabling microtome-free, direct digitization of entire tissue samples for improved 3D diagnostics and workflow efficiency), translational research (studying disease biology across 3D volumes enabling detection of immune cell infiltration patterns and characterization of novel biomarkers), drug development (understanding mechanisms of action and optimizing patient selection for clinical trial samples), AI-enabled clinical decision support (predicting treatment response and patient prognosis using AI-driven analysis of rich 3D imaging datasets). JENA, Germany & SEATTLE, May 06, 2025 --( BUSINESS WIRE )--ZEISS and Alpenglow Biosciences today announced a new partnership to jointly develop an inverted light-sheet microscope and bioinformatics pipeline tailored specifically for clinical applications. Alpenglow, a pioneering 3D spatial biology company specializing in open-top light-sheet microscopy, data processing, and AI-driven analysis for biopharma and clinical applications, has partnered with ZEISS, a global leader in light-sheet imaging technologies and visualization software – including ZEISS Lattice Lightsheet 7 and arivis software. Story Continues Dr. Albiez further emphasized, "At ZEISS, we are committed to driving innovation in imaging solutions that bridge the gap between research and clinical applications. This collaboration with Alpenglow marks a significant milestone in advancing workflows for clinical pathology. Together, we are introducing an integrated solution for analysing entire tissue samples and improving reproducibility to meet the evolving needs of both translational research and clinical settings. This collaboration will enable researchers and clinicians to gain deeper insights into tissue and cellular structures with greater efficiency and precision, ultimately facilitating more personalized and effective treatments." The partnership will create the fastest whole tissue imaging solution by combining exacting engineering and arivis visualization platform from ZEISS with Alpenglow's innovative data processing and AI capabilities. Once imaged, a GPU-accelerated imaging analytics pipeline could allow users to go from tissue to clinically impactful insights at the same time or faster than traditional pathology workflows. The generation of 3D images from entire tissues provides the perfect substrate for AI to make individualized treatment predictions for patients. Ultimately, these innovative technologies will deliver tools that streamline pathology workflows and enable earlier, more accurate clinical decision-making. About ZEISS ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue around 11 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (30 September 2024). For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future. With over 46,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 35 production facilities worldwide (30 September 2024). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG. Further information at ZEISS Research Microscopy Solutions ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA and China. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment. Further information at About Alpenglow Biosciences Alpenglow Biosciences is a 3D spatial biology company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D imaging technology. Their platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and clinical trial enrollment using their patented platform. See what you've been missing at View source version on Contacts Press contact ZEISS Research Microscopy Solutions Vybhav Sinha Phone: +49 3641 64 3949 Email: Alpenglow Biosciences Sarah Malik Phone: (206) 455-3170 Email: media@
Business Wire
06-05-2025
- Business
- Business Wire
New Inverted Light-Sheet Microscopy Platform for Research and Clinical Applications
JENA, Germany & SEATTLE--(BUSINESS WIRE)--ZEISS and Alpenglow Biosciences today announced a new partnership to jointly develop an inverted light-sheet microscope and bioinformatics pipeline tailored specifically for clinical applications. Alpenglow, a pioneering 3D spatial biology company specializing in open-top light-sheet microscopy, data processing, and AI-driven analysis for biopharma and clinical applications, has partnered with ZEISS, a global leader in light-sheet imaging technologies and visualization software – including ZEISS Lattice Lightsheet 7 and arivis software. ZEISS and Alpenglow Biosciences join forces to transform clinical pathology with cutting-edge light sheet microscopy and AI-driven analysis, enhancing patient care through precise treatment recommendations. Share By combining the industry-leading technologies of Alpenglow and ZEISS, the collaboration will enable the broader adoption of 3D pathology across research, translational and clinical applications. As part of the multi-phased collaboration, the companies will develop key applications in: Enhanced 3D pathology workflows (enabling microtome-free, direct digitization of entire tissue samples for improved 3D diagnostics and workflow efficiency), translational research (studying disease biology across 3D volumes enabling detection of immune cell infiltration patterns and characterization of novel biomarkers), drug development (understanding mechanisms of action and optimizing patient selection for clinical trial samples), AI-enabled clinical decision support (predicting treatment response and patient prognosis using AI-driven analysis of rich 3D imaging datasets). "Partnering with ZEISS represents a significant step forward in our mission to revolutionize pathology by extracting and analysing the wealth of information contained in every single cell of a biopsy, rather than relying on just a small fraction of the tissue," said Dr. Nicholas Reder, CEO of Alpenglow Biosciences. "ZEISS's long-standing history of innovation in light-sheet microscopy is the perfect complement to our cutting-edge software and AI capabilities. Together, we will innovate and expand our existing 3D pathology platform that not only advances the needs of biopharma but also transforms clinical practice." 'We are excited to collaborate with Alpenglow and leverage their deep expertise in AI and software development," said Dr. Michael Albiez, Head of ZEISS Research Microscopy Solutions. "This partnership combines Alpenglow's rapidly growing reputation with pharmaceutical companies and clinicians with the leadership of ZEISS in light-sheet microscopy, enabling the creation of powerful, fully integrated workflows for 3D pathology, from sample to analytics.' Dr. Albiez further emphasized, 'At ZEISS, we are committed to driving innovation in imaging solutions that bridge the gap between research and clinical applications. This collaboration with Alpenglow marks a significant milestone in advancing workflows for clinical pathology. Together, we are introducing an integrated solution for analysing entire tissue samples and improving reproducibility to meet the evolving needs of both translational research and clinical settings. This collaboration will enable researchers and clinicians to gain deeper insights into tissue and cellular structures with greater efficiency and precision, ultimately facilitating more personalized and effective treatments." The partnership will create the fastest whole tissue imaging solution by combining exacting engineering and arivis visualization platform from ZEISS with Alpenglow's innovative data processing and AI capabilities. Once imaged, a GPU-accelerated imaging analytics pipeline could allow users to go from tissue to clinically impactful insights at the same time or faster than traditional pathology workflows. The generation of 3D images from entire tissues provides the perfect substrate for AI to make individualized treatment predictions for patients. Ultimately, these innovative technologies will deliver tools that streamline pathology workflows and enable earlier, more accurate clinical decision-making. About ZEISS ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue around 11 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (30 September 2024). For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future. With over 46,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 35 production facilities worldwide (30 September 2024). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG. Further information at ZEISS Research Microscopy Solutions ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA and China. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment. Further information at About Alpenglow Biosciences Alpenglow Biosciences is a 3D spatial biology company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D imaging technology. Their platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and clinical trial enrollment using their patented platform. See what you've been missing at
